智通财经APP获悉，医药股早盘涨幅居前，截至发稿，再鼎医药(09688)涨14.86%，报25.5港元；和铂医药-B(02142)涨10.07%，报7.87港元；荣昌生物(09995)涨8.22%，报30.95港元；君实生物(01877)涨8.1%，报15.22港元；来凯医药-B(02105)涨7.71%，报11.46港元。
广发证券认为，当前资本市场的关注焦点正悄然从传统的地产和政策周期转向更具长期战略意义的中美科技博弈。该行建议重视港股创新药的配置价值，原因在于：核心逻辑一：中国创新药出海的全球竞争优势正在凸显；核心逻辑二：当前关税政策对创新药影响远小于其他成长性板块；核心逻辑三：政策及监管态度逐步转向对板块有利的情形。2023年下半年以来，政策层面出现了一系列积极信号，标志着行业监管思路的调整，包括但不限于集采规则优化、创新药支持政策加码、医疗反腐常态化与纠偏。
此外，财报层面：头部港股创新药公司受益于License-out放量，营收和利润稳步增长。估值层面：年初以来科技股的放量大涨之后，医药板块相比于其他成长行业，估值处于相对安全的区间。该行表示，年初以来在DeepSeek的激励下，港股市场交投情形改善显著，相比之下，港股医药板块的关注度并不算高，对医药的基本面修复，市场定价或尚不充分。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.